Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report Intel FAQ API Sign In →
47 /100
MEDIUM RISK
Score updated Jul 29, 2026

AVLN — Avalyn Pharma Inc. Dilution Risk Tracker

Track AVLN dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track AVLN — Get alerts when the score changes →

As of July 29, 2026, Avalyn Pharma Inc. (AVLN) has a DilutionWatch DilutionScore of 47/100, rated MEDIUM dilution risk. Avalyn Pharma Inc. has a market capitalization of $1.28B, 44.33M shares outstanding.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

Score Breakdown

📋 Offering Ability
40
💰 Cash Runway
25
📊 Float Risk
65
⚠️ Warrant Exposure
40
🔄Convertible Debt

Dilution Forecast

☀️
Clear
No significant dilution signals
0%
No significant dilution signals detected for AVLN.
🔔 Track AVLN — Get forecast alerts →

Market Data

Market Cap$1.28B
Shares Outstanding44.33M
Float14.45M
Cash$123.13M
Debt$14.81M
Short InterestN/A

Institutional Holdings

52.9% institutional ownership
Source: Yahoo Finance · Detailed 13F holder data available for tracked tickers
🔔 Track AVLN for full holder detail →

Short Interest

Short Interest2.19M
Days to Cover5.6
% of Float15.2%
FINRA data as of Jul 15, 2026

Recent SEC Activity

xbrl XBRL WARRANT 2026-03-31
Full SEC filing analysis available with free account

Recent News

No recent news

What This Means for AVLN Shareholders

Avalyn Pharma Inc. (AVLN) has a DilutionScore of 47/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 29, 2026.

DilutionWatch's EDGAR monitoring for AVLN shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for AVLN in real-time, scanning EDGAR every 60 seconds. The DilutionWatch shows real-time score changes for AVLN alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.

Understanding AVLN's Dilution Risk Factors

Primary Risk Drivers

The most significant dilution risks for Avalyn Pharma Inc. stem from its Float Risk and Cash Runway factors. Float Risk is currently at a concerning level, indicating that a substantial portion of shares may be available for trading, which can lead to downward pressure on share price and increased potential for dilution through secondary offerings. Cash Runway scores moderately high, suggesting the company has limited cash reserves and may need to raise capital soon, increasing the likelihood of equity issuance. These two factors together create a scenario where the company could be forced to issue new shares to fund operations or growth, directly impacting existing shareholders' ownership percentage.

Factors Currently Not a Concern

Several risk indicators remain low and manageable for Avalyn Pharma Inc. The Offering Ability, Warrant Exposure, and Convertible Note Risk are all below average, indicating that the company is not currently in a position to issue large blocks of new shares or convert debt into equity at scale. However, changes such as filing an S-3 registration statement for a future offering, or announcing warrant exercises, could quickly elevate these scores. A 10-Q filing disclosing increased convertible note activity would also signal growing dilution risk.

SEC Filings to Watch

Several SEC filings are critical to monitor for signs of increasing dilution. An S-3 Registration Statement would indicate a planned large-scale equity offering, directly signaling potential share dilution. A 424B5 filing often follows such offerings and provides details on the new shares issued. An 8-K Item 1.01 may signal new equity issuance or capital structure changes that could impact existing shareholders. Additionally, a 10-Q quarterly report showing increased convertible debt activity or warrant expirations would be red flags for future dilution.

How Dilution Happens

Dilution occurs when new shares are issued, reducing the percentage ownership of existing shareholders. For Avalyn Pharma Inc., if the company needs to raise capital due to a short cash runway, it might issue new shares through an offering or convert debt into equity via convertible notes or warrants. Each step increases the total number of outstanding shares, thereby decreasing the value and proportion of each existing share. The elevated Float Risk suggests that many shares are already available for trading, making it easier for the company to issue more shares without immediate market resistance but also increasing the risk of further dilution.

What Would Make This Worse

If Avalyn Pharma Inc. were to file an S-3 registration statement and subsequently complete a large equity offering, or if convertible notes are converted into common stock at scale, the company's dilution profile would worsen significantly. Additionally, if the cash runway deteriorates further and the company begins issuing warrants or converting debt regularly, it could lead to a rapid increase in share count. A 10-Q filing revealing increased capital structure complexity or an 8-K Item 1.01 announcement of a major financing round would mark a critical escalation in dilution risk.

Key Insight

Low scores indicate safer conditions, and monitoring for upward trends in key factors is essential to assess changing dilution risks.

How to Monitor AVLN for Dilution Risk

What This Risk Level Means

For a small-cap operating company like Avalyn Pharma Inc., a medium dilution risk score indicates that while the company is not currently in immediate danger, it has structural elements that could increase shareholder value erosion if not managed carefully. Small-cap companies often rely on equity financing to fund operations and growth, making them more susceptible to dilution pressures. With factors such as offering ability, float risk, warrant exposure, and convertible note risk all elevated, the company’s capital structure is fragile enough to warrant close attention.

What Typically Happens Next

Companies with this profile often proceed through equity financing mechanisms like shelf registrations or ATM programs to raise capital. Warrant exercises and convertible note conversions are common events that can significantly dilute existing shareholders. These actions typically occur in cycles, especially when a company is actively seeking funding for research, development, or operational expansion. Monitoring these activities is critical as they often precede sudden changes in ownership percentages.

Monitoring Playbook

To track AVLN effectively, use DilutionWatch to monitor its DilutionScore and key risk factors. Set alerts for any score increase above 50/100, and check updates weekly or bi-weekly. When thresholds are hit, review recent SEC filings, particularly Form S-1, S-3, and 8-Ks, for new equity offerings or warrant activity. Additionally, monitor Shelf & ATM Monitor for signs of upcoming capital raises.

Early Warning Signals

Three specific warning signals include: 1) A sudden spike in the Warrant Exposure factor score, indicating increased warrant issuance or exercise activity; 2) An uptick in Offering Ability, suggesting a potential new equity offering is in progress; and 3) A marked increase in Convertible Note Risk, signaling that convertible debt may be nearing conversion. These changes often reflect growing capital needs and can precede significant dilution events.

What a Positive Resolution Looks Like

A positive shift in AVLN’s profile would occur if the company completes a capital raise, reducing reliance on future equity issuance. Alternatively, if warrant or convertible note obligations expire without conversion, the dilution risk would decrease significantly. A reduction in Float Risk or Offering Ability scores, due to decreased planned offerings, would also indicate improved investor protection and lower dilution exposure.

Watch For

Any sudden changes in offering ability or warrant exposure scores, especially if they exceed 60/100, as these often precede major dilution events.

Full SEC filing analysis available with free account  →
Track AVLN Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking AVLN — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for AVLN
AVLN Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.